Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Youth Overdose & Use Reduction in Rural Systems (YOURS)

22 septembre 2026 mis à jour par: Kym Ahrens, Seattle Children's Hospital

YOURS Study: Youth Overdose & Use Reduction in Rural Systems

The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.

The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.

The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.

Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.

Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.

Aperçu de l'étude

Description détaillée

Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.

Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.

Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.

Type d'étude

Interventionnel

Inscription (Estimé)

550

Phase

  • N'est pas applicable

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

14 ans à 18 ans (Enfant, Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Youth age 14-18
  • Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
  • Received a REDCap link or QR code and study participation code from authorized county staff

Exclusion Criteria:

  • Youth age 13 and under
  • Youth who do not receive a study participation code from an authorized county contact
  • Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intervention: YOURS Navigator Program

The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties.

Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.

Autres noms:
  • Gestion des soins
  • ACRA/ACC
  • Assertive Continuing Care (ACC)
Aucune intervention: Usual Care

No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overdose Prevention Knowledge
Délai: 3- and 6-months

Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome.

3- and 6-months
Presence of use past 30 days (Yes/No)
Délai: 3- and 6-months

Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days

3- and 6-months
Number of days using alcohol and cannabis
Délai: 3- and 6-months

In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol.

3- and 6-months
Number of youth receiving case management, mental health, or substance use prevention services
Délai: Through study completion, up to 30 months

Primary implementation outcome - county level

Through study completion, up to 30 months
Number of naloxone kits distributed
Délai: Through study completion, up to 30 months

Primary implementation outcome - county level

Through study completion, up to 30 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of days of using other individual non-alcohol/non-cannabis substances
Délai: 3- and 6- months

Measure taken from the HEAL Prevention Cooperative Common Core Measures

3- and 6- months
Substance use refusal self-efficacy
Délai: 3- and 6-months

How confident youth are resisting substances.

3- and 6-months
Percent of youth reporting receipt of naloxone
Délai: 3 months

Percent of youth receiving naloxone, a medication to reverse an opioid overdose.

3 months
Number of youth receiving overdose prevention education
Délai: Through study completion, up to 30 months

Secondary implementation outcome - county level

Through study completion, up to 30 months
Number of court staff receiving overdose prevention education
Délai: Through study completion, up to 30 months

Secondary implementation outcome - county level

Through study completion, up to 30 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Presence of non-fatal overdose
Délai: 3- and 6-months

Exploratory outcome, investigator-developed

3- and 6-months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

1 février 2029

Achèvement de l'étude (Estimé)

1 février 2029

Dates d'inscription aux études

Première soumission

16 juillet 2026

Première soumission répondant aux critères de contrôle qualité

22 septembre 2026

Première publication (Réel)

29 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2026-007-SCH
  • R61DA061846 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).

Délai de partage IPD

IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).

Critères d'accès au partage IPD

Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner